

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a polynucleotide having at least 95% identity to a member selected from the group consisting of:
  - (a) a polynucleotide encoding a polypeptide comprising amino acid 2 to 92 of SEQ ID NO:2; and
  - (b) the complement of (a).
2. The isolated polynucleotide of claim 1 wherein said member is (a).
3. The isolated polynucleotide of claim 1 wherein said member is (a) and the polypeptide comprises amino acids 1 to 92 of SEQ ID NO:2.
4. The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence identical to amino acids 2 to 92 of SEQ ID NO:2.
5. The isolated polynucleotide of claim 1, wherein the polynucleotide is DNA.
6. The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino sequence identical to amino acids 1 to 92 of SEQ ID NO:2.
7. The isolated polynucleotide of claim 1, wherein said polynucleotide is RNA.
8. A method of making a recombinant vector comprising inserting the isolated polynucleotide of claim 2 into a vector, wherein said polynucleotide is DNA.

9. A recombinant vector comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA'.

10. A recombinant host cell comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA.

11. A method for producing a polypeptide comprising expressing from the recombinant cell of claim 10 the polypeptide encoded by said polynucleotide.

12. A process for producing a polypeptide comprising:  
expressing from a recombinant cell  
containing the polynucleotide of claim 4 the polypeptide  
encoded by said polynucleotide.

13. A process for producing a polypeptide comprising:  
expressing from a recombinant cell  
containing the polynucleotide of claim 6 the polypeptide  
encoded by said polynucleotide.

14. The isolated polynucleotide of claim 1 comprising nucleotides 79 to 351 of SEQ ID NO:1.

15. The isolated polynucleotide of claim 1 comprising nucleotides 76 to 351 of SEQ ID NO:1.

16. The isolated polynucleotide of claim 1 comprising the nucleotides of the sequence of SEQ ID NO:1.

17. An isolated polynucleotide comprising a polynucleotide having at least a 95% identity to a member selected from the group consisting of:

(a) a polynucleotide encoding the same mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97304; and

(b) the complement of (a).

18. The isolated polynucleotide of claim 17, wherein the member is (a).

19. The isolated polynucleotide of claim 17, wherein said polynucleotide comprises DNA identical to the coding portion of the human cDNA in ATCC Deposit No. 97304 which encodes a mature polypeptide.

20. An isolated polypeptide comprising:

a mature polypeptide having an amino acid sequence encoded by a polynucleotide which is at least 95% identical to the polynucleotide of claim 4.

21. The isolated polypeptide of claim 20, comprising amino acids 2 to 92 of sequence of SEQ ID NO:2.

22. The isolated polypeptide of claim 20, comprising amino acids 1 to 92 of sequence of SEQ ID NO:2.

23. An isolated polypeptide comprising:

a mature polypeptide encoded by a polynucleotide which is at least 95% identical to the human cDNA contained in ATCC Deposit No. 97304.

24. The isolated polypeptide of claim 23 comprising the mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97304.

25. An antibody against the polypeptide of claim 20.

26. An antagonist against the polypeptide of claim 20.
27. An agonist to the polypeptide of claim 20.
28. A method for the treatment of a patient having need of a chemotactic cytokine I comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 20.
29. The method of Claim 28 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.
30. A method for the treatment of a patient having need to inhibit a chemotactic cytokine I polypeptide comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 26.
31. A method for the treatment of a patient having need of a chemotactic cytokine I polypeptide comprising: administering to the patient a therapeutically effective amount of the agonist of Claim 27.
32. A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of claim 20 comprising:  
determining a mutation in the nucleic acid sequence encoding said polypeptide.
33. A diagnostic process comprising:  
analyzing for the presence of the polypeptide of claim 20 in a sample derived from a host.

34. A method for identifying compounds which bind to and activate or inhibit a receptor for the polypeptide of claim 20 comprising:

contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound to be screened under conditions to permit binding to the receptor; and

determining whether the compound binds to and activates or inhibits the receptor by detecting the presence or absence of a signal generated from the interaction of the compound with the receptor.

*Added Cu >*

09227854-011199